Perimount Pericardial
Bioprosthesis for Aortic Calcified Stenosis: Michel R. Aupart, Alain Mirza, Yvon A. Meurisse, Agnes L. Sirinelli,
Paul H. Neville, Michel A. Marchand |
|||||||
Background and aim of the study: Aortic stenosis (AS)
is the most important cause of aortic valve disease, its prevalence increasing
with patient age. The present study formed part of a long-term evaluation
on use of the Perimount pericardial valve for aortic calcified stenosis. |
Among the 725 patients followed, 80% were in sinus rhythm
and 98% in NYHA classes I or II. Valve-related complications included
39 thromboembolic episodes, 24 endocarditis, 22 anticoagulant-related
hemorrhage, 28 reoperations, and 19 structural valve failures. A total
of 54 patients died from valve-related causes (13 embolic events, two
endocarditis, two hemorrhage, one structural failure, 36 unknown causes),
and 57 died from cardiac failure. Neither thrombosis nor hemolysis was
observed. At 18 years, freedom from embolism was 92 ± 2%, from
endocarditis 93 ± 4%, from hemorrhage 95 ± 2%, from reoperation
62 ± 11%, from valve failure 68 ± 12%, and from all complications
47 ± 8%. Among patients aged >60 years, the 18-year actuarial
freedom from reoperation was 76 ± 14%, and from valve failure
85 ± 8%. The Journal of Heart Valve Disease 2006;15:768-776 |
||||||
|
|||||||